Study M483
Study name | Pan JX 2018 |
Title | Diagnosis of major depressive disorder based on changes in multiple plasma neurotransmitters: a targeted metabolomics study |
Overall design | Here, using a GC-MS coupled with LC-MS/MS-based targeted metabolomics approach, we simultaneously quantified the levels of 19 plasma metabolites involved in GABAergic, catecholaminergic, and serotonergic neurotransmitter systems in 50 first-episode, antidepressant drug-naive major depressive disorder (MDD) subjects and 50 healthy controls to identify potential metabolite biomarkers for MDD (training set). Moreover, an independent sample cohort comprising 49 MDD patients, 30 bipolar disorder (BD) patients and 40 healthy controls (testing set) was further used to validate diagnostic generalizability and specificity of these candidate biomarkers. |
Study Type | Type1; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV-TR diagnosed MDD |
Sample size | 189 |
Tissue | Peripheral; Blood; Plasma; |
Platform | MS-based; GC-MS: Agilent 7890 A/5975 C Inert Triple Axis Detector (Agilent, USA); MS-based; LC-MS: ACQUITY UPLC and AB Sciex Triple Quad6500 mass spectrometry system; |
PMID | |
DOI | |
Citation | Pan JX, Xia JJ, Deng FL, et al. Diagnosis of major depressive disorder based on changes in multiple plasma neurotransmitters: a targeted metabolomics study. Transl Psychiatry. 2018;8(1):130. |
Metabolite | Gamma-Aminobutyric acid; |
